摘要
三七是我国常用的大宗中药材,其中化学成分类型丰富,包括三萜皂苷、黄酮、氨基酸、多糖、挥发油等类成分,传统认为三萜皂苷类成分为其主要药效成分。从化学成分和药理作用等几个方面对三七的研究现状进行综述,在此基础上,根据中药质量标志物(quality marker,Q-Marker)理论,探究人参属药用植物亲缘关系,结合三七生源途径、传统功效、传统药性等研究对三七Q-Marker进行预测分析,预测三七皂苷R1、人参皂苷Rg1、人参皂苷Re、人参皂苷Rb1、人参皂苷Rg2、人参皂苷Rd、三七素可作为Q-Marker的选择,以期为三七的质量控制和新标准的制定提供科学依据。
Sanqi(Notoginseng Radix et Rhizoma)is a commonly used traditional Chinese medicinal material that enjoys abundant chemical constituents including triterpene saponins,flavonoids,amino acids,polysaccharides,volatile oils,and so on.Traditionally,triterpene saponins are regarded as its main pharmacodynamic components.The current research status of Notoginseng Radix et Rhizoma will be summarized in the aspects of chemical composition and pharmacological effects.On this basis,the prediction and analysis of the Q-Marker of Notoginseng Radix et Rhizoma will be performed through researches on the genetic relations of Panax according to the quality marker(Q-Marker)theory of TCM combined with biosynthetic pathways,traditional efficacy and medicinal properties.It was predicted that notoginsenoside R1,ginsenoside Rg1,ginsenoside Re,ginsenoside Rb1,ginsenoside Rg2,ginsenoside Rd,and ginsenoside could be selected as Q-marker,which is expected to provide the scientific basis for qualitative and quantitative analysis of the effective components of Notoginseng Radix et Rhizoma and the development of a new standard.
作者
刘耀晨
张铁军
郭海彪
许浚
林娟
张洪兵
韩彦琪
王德勤
李楚源
刘昌孝
LIU Yao-chen;ZHANG Tie-jun;GUO Hai-biao;XU Jun;LIN Juan;ZHANG Hong-bing;HAN Yan-qi;WANG De-qin;LI Chu-yuan;LIU Chang-xiao(Tianjin Medical University,Tianjin 300070,China;National&Local United Engineering Laboratory of Modem Preparation and Quality Control Technology of Traditional Chinese Medicine,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Tianjin Key Laboratory of Quality Marker of Traditional Chinese Medicine,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co.,Ltd.,Guangzhou 510515,China)
出处
《中草药》
CAS
CSCD
北大核心
2021年第9期2733-2745,共13页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金重点项目(81830111)
广东省重点领域研发计划(2020B1111110002)
中医药国际合作专项(0610-2040NF020928)。
